Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ADH -1 (Exherin™)
ADH-1 · 5 trials · 21 indications
The incidence rates of adverse events will be described by dose level. The frequency of occurrence of overall toxicity, categorized by toxicity grades, will be described.
| Arm | Type | Description |
|---|---|---|
| Treatment (ADH-1, cisplatin, gemcitabine hydrochloride) | EXPERIMENTAL | Patients receive ADH-1 IV over 20-80 minutes on days 1, 4, 8, 11, 15, and 18, cisplatin IV and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease may receive maintenance therapy with cisplatin and gemcitabine hydrochloride. |
| Name | Type | Description |
|---|---|---|
| ADH -1 (Exherin™) | DRUG | - |
| ADH-1 | DRUG | Given IV |
| Cisplatin | DRUG | Given IV |
| Gemcitabine Hydrochloride | DRUG | Given IV |
| Laboratory Biomarker Analysis | OTHER | Correlative studies |
| melphalan | DRUG | By Isolated Limb Infusion (ILI), Lower Extremity: 7.5 mg/L (Limb Volume), Day 1 or Upper Extremity: 10 mg/L (Limb Volume), Day 1 |
| ADH -1 and carboplatin | DRUG | - |
| ADH -1 and docetaxel | DRUG | - |
| ADH -1 and capecitabine | DRUG | - |
Inclusion Criteria: * Signed written informed consent * Male and female patients \> or = 18 years of age with a solid tumor(s) refractory to standard curative therapy or for which no curative therapy exists * Histologically proven advanced and/or metastatic solid tumor of one of the following histo...
Top 13 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 9 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCB000928 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | Momelotinib |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
ADH-1 is an investigational small molecule developed by Fennec Pharmaceuticals Inc. (ticker FENC) for oncology indications. It has been studied in Phase 1 clinical trials in patients with solid tumors, including ampulla of Vater adenocarcinoma and other neoplasms. All four of its recorded trials are completed, and it is not currently approved.
ADH-1 has been studied in Phase 1 trials for ampulla of Vater adenocarcinoma and other neoplasms. One trial, NCT01825603, evaluated ADH-1 with gemcitabine hydrochloride and cisplatin in metastatic pancreatic or biliary tract cancer, a group that includes ampulla of Vater adenocarcinoma. The drug remains investigational and is not approved for this use.
ADH-1 is developed by Fennec Pharmaceuticals Inc., which trades under the ticker FENC. The company has sponsored Phase 1 studies of the agent in solid tumors and in combination regimens. ADH-1 is also referred to as Exherin.
ADH-1 is in Phase 1 clinical development. All four of its recorded trials are Phase 1 studies, and all four are completed, with no active trials. The studies enrolled a total of 56 patients across the reported trials. ADH-1 is investigational and has not been approved by the FDA.
ADH-1 has been evaluated in four completed Phase 1 trials: NCT01825603 with gemcitabine and cisplatin in pancreatic or biliary tract cancer, NCT00421811 with normothermic isolated limb infusion of melphalan, NCT00390676 with carboplatin, docetaxel or capecitabine, and NCT00265057 given intravenously to patients with solid tumors.
Yes, ADH-1 is also known as Exherin. The names ADH-1 and Exherin refer to the same investigational agent. It has also been studied in combination regimens, including ADH-1 with carboplatin, which appear in trial listings under those combination names.